The history of RIEMSER is closely connected to the Friedrich-Löffler-Institut on the island Riems. Although its origins are in veterinary medicines, in recent years in particular RIEMSER has increasingly established itself as a strong player in the field of human medicine.
By selling our veterinary medicines business and by outsourcing our production (except in the field of tuberculosis therapy), we were able to focus our efforts on our strengths in marketing and distribution. Since 2009, RIEMSER has been pursuing the goal of expanding its product range of medicines for the treatment of serious diseases in the fields of oncology, infectiology and neurology.
In addition to this, our strengths also lie in the distribution of established medicines in the cardiovascular field, in dermatology, rheumatology, tuberculosis therapy, or medicines for treating obesity or primary hyperhidrosis. Medical devices and food supplements complement our portfolio.
As part of its clear growth strategy, RIEMSER is constantly searching for innovative products or interesting partnerships. In 2014 and 2015, the subsidiaries Keocyt domiciled in France and Intrapharm domiciled in England joined the RIEMSER group. The organisation thus covers important markets in Europe. RIEMSER is open to entering into new partnerships, especially in Southern Europe and in the Scandinavian countries. In 2016, by purchasing the CNS division of Dolorgiet, RIEMSER continued to expand its product range to include the therapeutic field of neurology.
Our focus on specific therapeutic fields and on Europe makes us a powerful marketing and distribution partner. We concentrate on our core competences and effectively take advantage of the existing synergies between the therapeutic fields.